[HTML][HTML] Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial
BS Woods, N Hawkins, DA Scott - BMC medical research methodology, 2010 - Springer
Background Data on survival endpoints are usually summarised using either hazard ratio,
cumulative number of events, or median survival statistics. Network meta-analysis, an …
cumulative number of events, or median survival statistics. Network meta-analysis, an …
[HTML][HTML] Country-level cost-effectiveness thresholds: initial estimates and the need for further research
B Woods, P Revill, M Sculpher, K Claxton - Value in Health, 2016 - Elsevier
Background Cost-effectiveness analysis can guide policymakers in resource allocation
decisions. It assesses whether the health gains offered by an intervention are large enough …
decisions. It assesses whether the health gains offered by an intervention are large enough …
[HTML][HTML] Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee
Background There is limited information on the costs and benefits of alternative adjunct non-
pharmacological treatments for knee osteoarthritis and little guidance on which should be …
pharmacological treatments for knee osteoarthritis and little guidance on which should be …
[HTML][HTML] APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts
Background With the onset of prevention trials for individuals at high risk for Alzheimer
disease, there is increasing need for accurate risk prediction to inform study design and …
disease, there is increasing need for accurate risk prediction to inform study design and …
[HTML][HTML] Partitioned survival and state transition models for healthcare decision making in oncology: where are we now?
Abstract Objectives Partitioned survival models (PSMs) are routinely used to inform
reimbursement decisions for oncology drugs. We discuss the appropriateness of PSMs …
reimbursement decisions for oncology drugs. We discuss the appropriateness of PSMs …
[HTML][HTML] System-wide approaches to antimicrobial therapy and antimicrobial resistance in the UK: the AMR-X framework
K Abel, E Agnew, J Amos, N Armstrong… - The Lancet …, 2024 - thelancet.com
Antimicrobial resistance (AMR) threatens human, animal, and environmental health.
Acknowledging the urgency of addressing AMR, an opportunity exists to extend AMR action …
Acknowledging the urgency of addressing AMR, an opportunity exists to extend AMR action …
[HTML][HTML] Antimicrobial resistance: is health technology assessment part of the solution or part of the problem?
Antimicrobial resistance is a serious challenge to the success and sustainability of our
healthcare systems. There has been increasing policy attention given to antimicrobial …
healthcare systems. There has been increasing policy attention given to antimicrobial …
Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure
Objective To evaluate the cost-effectiveness of implantable cardioverter defibrillators (ICDs),
cardiac resynchronisation therapy pacemakers (CRT-Ps) and combination therapy (CRT-D) …
cardiac resynchronisation therapy pacemakers (CRT-Ps) and combination therapy (CRT-D) …
No study left behind: a network meta‐analysis in non–small‐cell lung cancer demonstrating the importance of considering all relevant data
N Hawkins, DA Scott, BS Woods, N Thatcher - Value in health, 2009 - Wiley Online Library
Objective: To demonstrate the importance of considering all relevant indirect data in a
network meta‐analysis of treatments for non–small‐cell lung cancer (NSCLC). Methods: A …
network meta‐analysis of treatments for non–small‐cell lung cancer (NSCLC). Methods: A …
[HTML][HTML] Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted …
BS Woods, E Sideris, MR Sydes, MR Gannon… - European urology …, 2018 - Elsevier
Background Results from large randomised controlled trials have shown that adding
docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate …
docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate …